Adjuvant vinorelbine and cisplatin after complete resection of stage II and III non-small cell lung cancer: long-term follow-up of our study of Japanese patients

Sonobe, Makoto; Hamaji, Masatsugu; Motoyama, Hideki; Menju, Toshi; Aoyama, Akihiro; Chen‐Yoshikawa, Toyofumi F.; Satô, Toshihiko; Date, Hiroshi

doi:10.1007/s00595-018-1646-7

Cited by 2 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Surgical resection is an effective treatment and provides adequate control for limited-stage GCCL [ 7 ]. Patients with NSCLC are at substantial risk for recurrence and death even after complete surgical resection [ 9 ]. The role of adjuvant chemotherapy for patients with resected stage IB disease is controversial [ 2 ].…”

Section: Discussionmentioning

confidence: 99%

Giant cell carcinoma of the lung successfully treated with surgical resection and adjuvant vinorelbine and cisplatin

Habib

Leifer

Azam

et al. 2018

Respiratory Medicine Case Reports

View full text Add to dashboard Cite

Giant Cell Carcinoma of the lung, a subtype of Sarcomatoid lung cancer is a poorly differentiated Non-Small-Cell Lung Cancer. GCCL has exceptionally aggressive characteristics, and its prognosis is much poorer than any other NSCLCs. Herein, we present a rare case of Giant Cell Carcinoma of lung treated successfully with surgical resection and adjuvant vinorelbine and cisplatin.A 48-year-old African American man with a history of smoking and chronic obstructive pulmonary disease was admitted to the hospital for chief complaints of shortness of breath. He was found to have a 3.5 cm × 3.3 cm x 2.8 cm cavitary right upper lobe mass which turned out to be poorly differentiated Giant Cell Carcinoma with extensive necrosis and deemed similar to stage 1b non-small cell lung cancer. He was successfully treated with right upper lobectomy and adjuvant chemotherapy with vinorelbine and cisplatin. He was followed for seven years with no evidence of recurrent disease.Giant Cell Carcinoma's existing literature is limited, and hence our case is reportable. Our case is unique because of the better outcome which we believe might be the result of early detection and treatment with surgical resection along with adjuvant chemotherapy. More studies are needed to deeply understand the need for adjuvant chemotherapy in stage 1 b GCCL, and proper guidelines are required for the indications of adjuvant chemotherapy in Stage 1b GCCL.

show abstract

Section: Discussionmentioning

confidence: 99%

Giant cell carcinoma of the lung successfully treated with surgical resection and adjuvant vinorelbine and cisplatin

Habib

Leifer

Azam

et al. 2018

Respiratory Medicine Case Reports

View full text Add to dashboard Cite

show abstract

“…Based on several clinical trials and a meta-analysis, adjuvant platinum-based chemotherapy (APC) after the complete resection of stage II-III NSCLC has proven clinical benefits and is now considered the standard of care (2)(3)(4)(5). However, approximately half of these patients experience disease recurrence after APC (6,7). Thus, it is important to identify a recurrence-or survival-associated indexes in these patients.…”

mentioning

confidence: 99%

Immunonutritional Indices in Non-small-cell Lung Cancer Patients Receiving Adjuvant Platinum-based Chemotherapy

et al. 2021

View full text Add to dashboard Cite

Background/Aim: Adjuvant platinum-based chemotherapy (APC) has been the standard of care for patients with non-small-cell lung cancer (NSCLC) who have undergone complete pulmonary resection. This study analyzed the clinical and prognostic significance of immunonutritional indices in NSCLC patients receiving APC. Patients and Methods: We retrospectively reviewed 110 patients from 2008 to 2016. Three immunonutritional indices were calculated: neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and prognostic nutritional index (PNI). Results: The median age was 64 years, and 66 patients were males. Each index showed a significant correlation with primary tumor length. NLR and PLR were significantly correlated with vascular invasion. Prognostic analyses revealed that each index was significantly correlated with postoperative recurrence-free survival (RFS) and overall survival (OS). On multivariate analyses, PNI was an independent predictor of RFS and OS. Conclusion: Host immunonutritional status may have a significant effect on the postoperative prognosis of NSCLC in patients receiving APC.

show abstract

Adjuvant vinorelbine and cisplatin after complete resection of stage II and III non-small cell lung cancer: long-term follow-up of our study of Japanese patients

Abstract: Adjuvant vinorelbine and cisplatin chemotherapy showed encouraging relapse-free and overall survival rates, and long-term safety in Japanese patients with resected NSCLC.

Cited by 2 publications

References 34 publications

Giant cell carcinoma of the lung successfully treated with surgical resection and adjuvant vinorelbine and cisplatin

Giant cell carcinoma of the lung successfully treated with surgical resection and adjuvant vinorelbine and cisplatin

Immunonutritional Indices in Non-small-cell Lung Cancer Patients Receiving Adjuvant Platinum-based Chemotherapy

Contact Info

Product

Resources

About